NCAM1 and neuroendocrine neoplasm: Subsequent immunohistochemistry analysis on these CDX tumors show positivity for commonly used markers for SCLC diagnosis: CD56, synaptophysin and chromogranin A, demonstrating the stability of the patient’s neuroendocrine tumor lineage (Fig. 1D).